– Clear path forward to initiate two planned Phase 2 clinical trials with KTX-1161 LITTLE ROCK, Ark.–(BUSINESS WIRE)–Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce it has completed a pre-Investigational New Drug (“IND”) interaction with the U.S. Food and Drug Administration (FDA) and received positive feedback on its … [Read more…]

Analysis from the ECZTRA 6 trial shows positive effects of Adbry on reducing Staphylococcus aureus skin colonization that contributes to skin irritation and infections, and improving gene expression toward a non-lesional skin profile in adolescents with moderate-to-severe atopic dermatitis (AD).1,2 Interim analysis of adolescent patients in the ECZTEND trial demonstrates that long-term use of Adbry … [Read more…]

– FDA Feedback on Seralutinib Phase 3 Clinical Trial Received; Expected to Commence in the Second Half of 2023 – – Topline Data from TORREY Study Open-Label Extension Expected in Mid-2023 – – Enrollment in GB5121 Phase 1b/2 Clinical Trial in PCNSL Paused – – Cash, cash equivalents and marketable securities totaled $256 million at … [Read more…]

BOSTON–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2022 financial results and provide a corporate update on Wednesday, March 22, 2023, at 8:30 a.m. Eastern/5:30 a.m. Pacific. Conference Call and Webcast: … [Read more…]

MILWAUKEE–(BUSINESS WIRE)–Physicians Realty Trust (NYSE: DOC) (the “Company”) announced today that the Company’s Board of Trustees has authorized, and the Company has declared, a quarterly cash dividend of $0.23 per common share and unit for the quarter ending March 31, 2023. “We are proud to declare and pay our 39th consecutive quarterly dividend. We believe … [Read more…]

Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia MILAN–(BUSINESS WIRE)–Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies … [Read more…]

Universities of Warwick and Birmingham to receive 1.2 GHz NMRs for Enabling Life-Science and Green-Tech Research throughout the United Kingdom COVENTRY, United Kingdom–(BUSINESS WIRE)–$BRKR #BRKR–Bruker announces that the United Kingdom is expanding its fundamental research infrastructure with recent orders for two 1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometers for the University of Warwick and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “2023 MedDev eMarketing Summit” conference has been added to ResearchAndMarkets.com’s offering. Now in its 7th year, the popular Medical Device Industry’s one-of-a-kind ‘TED-style’ digital marketing leadership Summit is back this May in beautiful San Diego! Join us and advance your ENTIRE TEAM with two years’ worth of new digital marketing strategies and expertise … [Read more…]

Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress 83% overall survival at two years vs. 34.3% OS from institutional database 17.95 months median progression-free survival vs. 5.8 months PFS in historical group BEIJING & BURLINGTON, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed … [Read more…]

OTTAWA, Ontario–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the first quarter of 2023. First Quarter January 31, … [Read more…]